Relmada Therapeutics Inc (RLMD) 1.3900 $RLMD
Relmada Therapeutics' d-Methadone Receives Orphan Drug Designation for Management of Postherpetic Neuralgia
PR Newswire - Tue Jun 07, 7:30AM CDT
Relmada Therapeutics, Inc. (OTCQB: RLMD), a clinical-stage company developing novel therapies for the treatment of chronic pain, announced today that d-Methadone (dextromethadone, REL-1017), a N-methyl-d-aspartate (NMDA) receptor antagonist in development as a treatment for both depression and chronic neuropathic pain, has received Orphan Drug designation from the U.S. Food and Drug Administration (FDA) for the management of postherpetic neuralgia. Postherpetic neuralgia (PHN) is a painful neuropathic condition resulting from an outbreak of the herpes zoster virus, otherwise known as shingles.
Relmada Therapeutics to Present at the LD Micro Invitational Conference
PR Newswire - Wed Jun 01, 7:30AM CDT
Relmada Therapeutics, Inc. (OTCQB: RLMD), a clinical-stage company developing novel therapies for the treatment of chronic pain, announced today that it will present at the LD Micro Invitational Conference on Tuesday, June 7, 2016 at the Luxe Sunset Bel Air Hotel in Los Angeles, CA.
OTCQX and OTCQB Companies to Present at 2016 Marcum MicroCap Conference
PR Newswire - Tue May 31, 5:49PM CDT
OTC Markets Group Inc. (OTCQX: OTCM), operator of financial markets for 10,000 U.S. and global securities, today announced the lineup of OTCQX® Best and OTCQB® Venture Market companies presenting at the Marcum MicroCap Conference, taking place June 1-2nd at the Grand Hyatt New York. The Marcum MicroCap Conference, is dedicated to providing a forum where publicly traded companies with less than $500 million in market capitalization can network with the investment community. The Conference will feature presentations by CEOs and CFOs from various industry sectors, expert panels, and the opportunity to meet with management of presenting companies on a one-on-one basis.
LTEA: 4.39 (+0.18)
Relmada Therapeutics to Present at the 5th Annual Marcum MicroCap Conference
PR Newswire - Thu May 26, 7:30AM CDT
Relmada Therapeutics, Inc. (OTCQB: RLMD), a clinical-stage company developing novel therapies for the treatment of chronic pain, announced today that it will present at the 5th Annual Marcum MicroCap Conference on Thursday, June 2, 2016 in New York City at the Grand Hyatt Hotel.
Relmada Therapeutics Announces Promotion of Michael D. Becker to Chief Financial Officer
PR Newswire - Mon May 16, 7:30AM CDT
Relmada Therapeutics, Inc. (OTCQB: RLMD), a clinical-stage company developing novel therapies for the treatment of chronic pain, today announced the promotion of Michael D. Becker to chief financial officer, effective as of May 11, 2016.
Relmada Therapeutics Announces Results of In Vivo Study Showing d-Methadone has Antidepressant-like Effects
PR Newswire - Wed May 04, 7:30AM CDT
Relmada Therapeutics, Inc. (OTCQB: RLMD), a clinical-stage company developing novel therapies for the treatment of chronic pain, today announced the results of an in vivo study showing that administration of d-Methadone (REL-1017), a N-methyl-d-aspartate (NMDA) receptor antagonist, results in antidepressant-like effects. Results are shown to be comparable to those achieved in similar treatment models using ketamine.
Relmada Therapeutics to Present at the Joseph Gunnar "Pioneers 2016" Conference
PR Newswire - Thu Apr 28, 7:30AM CDT
Relmada Therapeutics, Inc. (OTCQB: RLMD), a clinical-stage company developing novel therapies for the treatment of chronic pain, today announced that it will present at the Joseph Gunnar "Pioneers 2016" Conference on May 5, 2016 at the New York Palace Hotel in New York City.
Relmada Therapeutics Provides Additional Details Regarding Upcoming R&D Day
PR Newswire - Tue Apr 26, 7:30AM CDT
Relmada Therapeutics, Inc. (OTCQB: RLMD), a clinical-stage company developing novel therapies for the treatment of chronic pain, today announced that it will hold its first R&D Day on May 4, 2016, from 10:00 a.m. to 12:00 p.m.
Relmada Therapeutics' Michael Becker Interviewed by The Life Sciences Report
Marketwired - Thu Apr 21, 8:02AM CDT
To treat chronic pain without risk of addiction is to straddle a knife's edge. But Relmada Therapeutics Inc. (OTCQB: RLMD) has a small fleet of compounds in development that address both sides of an issue that has become a newsmaker, given the recent upsurge in heroin addiction and the ever-present conundrum of alleviating severe pain in chronic disease and after surgery. In this interview with The Life Sciences Report, Relmada's Michael Becker describes the company's programs, which are advancing steadily toward the marketplace.
Relmada Therapeutics, Inc. Provides Update on Nasdaq Up-Listing Process
PR Newswire - Thu Apr 14, 7:30AM CDT
Relmada Therapeutics, Inc. (OTCQB: RLMD) a clinical-stage company developing novel therapies for the treatment of chronic pain, today provided investors with an update regarding the Company's qualification for up-listing to The Nasdaq Capital Market ("Nasdaq"
. As previously disclosed, the Company submitted an initial listing application with Nasdaq in the second half of 2015. The Company now believes that it satisfies each of the exchange's applicable listing requirements, with the exception of the $4.00 bid price requirement. In accordance with the Nasdaq Listing Rules, the Company's stock price must close at or above $4.00 per share for 30 of the most recent 60 trading days in order for the Company to be eligible to list.
UPDATE -- OTCQX and OTCQB Companies to Present at 2016 Roth Conference
PR Newswire - Mon Mar 14, 6:00AM CDT
OTC Markets Group Inc. (OTCQX: OTCM), operator of financial markets for 10,000 U.S. and global securities, today announced the lineup of OTCQX® Best and OTCQB® Venture Market companies presenting at the 28th Annual ROTH Conference, taking place March 13-16 at the Ritz-Carlton in Dana Point, CA. The ROTH Conference, hosted by ROTH Capital Partners, LLC, is one of the largest small-cap investment conferences in the U.S., featuring presentations by senior executives from hundreds of public and private companies in a wide variety of sectors.
VRAY: 3.37 (+0.13), DMPI: 6.80 (-0.03), CDXC: 4.00 (-0.39), EKSO: 3.85 (-0.10)
OTCQX And OTCQB Companies To Present At 2016 ROTH Conference
PR Newswire - Thu Mar 10, 6:00AM CST
OTC Markets Group Inc. (OTCQX: OTCM), operator of financial markets for 10,000 U.S. and global securities, today announced the lineup of OTCQX® Best and OTCQB® Venture Market companies presenting at the 28th Annual ROTH Conference, taking place March 13-16 at the Ritz-Carlton in Dana Point, CA. The ROTH Conference, hosted by ROTH Capital Partners, LLC, is one of the largest small-cap investment conferences in the U.S., featuring presentations by senior executives from hundreds of public and private companies in a wide variety of sectors.
VRAY: 3.37 (+0.13), DMPI: 6.80 (-0.03), CDXC: 4.00 (-0.39), EKSO: 3.85 (-0.10)
Relmada Therapeutics to Present at the 18th Annual BIO CEO & Investor Conference
PR Newswire - Tue Feb 02, 7:00AM CST
Relmada Therapeutics, Inc. (OTCQB: RLMD) a clinical-stage company developing novel therapies for the treatment of chronic pain, announced today that the Company will present at the 18th Annual BIO CEO & Investor Conference on Monday, February 8th at 3:30 p.m. Eastern Time. The conference will take place at the Waldorf Astoria Hotel in New York City.
Relmada Therapeutics Files Amended Complaint Against Laidlaw and Its Principals, Matthew Eitner and James Ahern
PR Newswire - Tue Jan 26, 6:00AM CST
Relmada Therapeutics, Inc. (OTCQB: RLMD) ("Relmada" or the "Company", a clinical-stage company developing novel therapies for the treatment of chronic pain, today announced that it has filed a motion to amend its complaint against Laidlaw & Company (UK) Ltd. ("Laidlaw" in the U.S. District Court for the District of Nevada. The motion to file an amended complaint is part of the lawsuit that the Company had previously filed in the Nevada District Court. The amended complaint includes an additional legal claim based on Laidlaw's breach of the fiduciary duty that it owed to Relmada when Laidlaw disclosed confidential information that it acquired in its capacity as the Company's investment banker. Relmada is also seeking monetary damages arising from fees and costs that it incurred responding to Laidlaw's false and misleading proxy materials in December 2015.
Relmada Therapeutics Selected to Present at 2016 Biotech Showcase(TM) in San Francisco
PR Newswire - Mon Jan 11, 7:00AM CST
Relmada Therapeutics, Inc. (OTCQB: RLMD) a clinical-stage company developing novel therapies for the treatment of chronic pain, announced today that the company has been selected to present at the 8th Annual Biotech Showcase(TM) Conference at 2:00 PM Pacific Time (5:00 PM Eastern Time) on Wednesday, January 13, 2016. The presentation will take place in Track C - Mission II at the Parc 55 Hotel in San Francisco.
Relmada Therapeutics Successfully Completes Multiple Ascending Dose Study of d-Methadone for Neuropathic Pain
PR Newswire - Mon Jan 04, 7:00AM CST
Relmada Therapeutics, Inc. (OTCQB: RLMD) ("Relmada" or the "Company), a clinical-stage company developing novel therapies for the treatment of chronic pain, announced today that it completed its multiple ascending dose ("MAD" study with d-Methadone (dextromethadone, REL-1017), its novel, N-methyl-D-aspartate ("NMDA" receptor antagonist being developed for the treatment of neuropathic pain. Relmada previously completed a single ascending dose ("SAD" study in March 2015. The design of the Company's Phase II proof-of-concept study in neuropathic pain, anticipated to start in the first half of 2016, will be based on this study's findings.
Relmada Therapeutics Announces Results of Annual Meeting of Stockholders
PR Newswire - Wed Dec 30, 10:55AM CST
Relmada Therapeutics, Inc. (OTCQB: RLMD) ("Relmada" or "the Company", a clinical-stage company developing novel therapies for the treatment of chronic pain, today announced that, at the Company's 2015 Annual Meeting of Stockholders, Relmada stockholders voted to elect all of Relmada's director nominees: Shreeram Agharkar, PhD, and Maged Shenouda, R. Ph., MBDA. The final tabulation indicates that more than 94% of votes cast at the Annual Meeting were in support of Messrs. Agharkar and Shenouda.
Relmada Therapeutics Recommends Stockholders Vote "FOR" Relmada's Director Nominees on the WHITE Proxy Card Today
PR Newswire - Mon Dec 28, 7:30AM CST
Relmada Therapeutics, Inc. (OTCQB: RLMD) ("Relmada" or the "Company", a clinical-stage company developing novel therapies for the treatment of chronic pain, today reiterated its Board's unanimous recommendation that stockholders vote "FOR" the Company's highly qualified, independent director nominees - Shreeram Agharkar, PhD, and Maged Shenouda R. Ph., MBA - on the WHITE proxy card today.
U.S. Federal Court Grants Preliminary Injunction Against Laidlaw & Company and its Principals Matthew Eitner and James Ahern
PR Newswire - Wed Dec 23, 7:30AM CST
Relmada Therapeutics, Inc. (OTCQB: RLMD) ("Relmada" or the "Company", a clinical-stage company developing novel therapies for the treatment of chronic pain, announced that following a hearing, the U.S. District Court for the District of Nevada granted Relmada's request and granted a Preliminary Injunction against Laidlaw & Company (UK) Ltd. and its principals, Matthew Eitner and James Ahern. The Court Order enjoins Laidlaw and Messrs. Eitner and Ahern from "continuing to disseminate false and misleading proxy materials."
Corrected Press Release--Shareholder Value Creation Committee Will Continue To Fight For Shareholder Rights
PR Newswire - Mon Dec 21, 2:10PM CST
The Committee of Relmada Shareholders for Value Creation, (the Shareholder Value Creation Committee) issued its press release on December 11, 2015, which press release omitted a sentence regarding the retraction of certain previously issued open letters to shareholders and characterized the temporary restraining order as preventing the solicitation of proxies, the characterization of which is being corrected herein. The corrected press release is as follows:
Relmada Therapeutics' d-Methadone Receives Orphan Drug Designation for Management of Postherpetic Neuralgia
PR Newswire - Tue Jun 07, 7:30AM CDT
Relmada Therapeutics, Inc. (OTCQB: RLMD), a clinical-stage company developing novel therapies for the treatment of chronic pain, announced today that d-Methadone (dextromethadone, REL-1017), a N-methyl-d-aspartate (NMDA) receptor antagonist in development as a treatment for both depression and chronic neuropathic pain, has received Orphan Drug designation from the U.S. Food and Drug Administration (FDA) for the management of postherpetic neuralgia. Postherpetic neuralgia (PHN) is a painful neuropathic condition resulting from an outbreak of the herpes zoster virus, otherwise known as shingles.
Relmada Therapeutics to Present at the LD Micro Invitational Conference
PR Newswire - Wed Jun 01, 7:30AM CDT
Relmada Therapeutics, Inc. (OTCQB: RLMD), a clinical-stage company developing novel therapies for the treatment of chronic pain, announced today that it will present at the LD Micro Invitational Conference on Tuesday, June 7, 2016 at the Luxe Sunset Bel Air Hotel in Los Angeles, CA.
OTCQX and OTCQB Companies to Present at 2016 Marcum MicroCap Conference
PR Newswire - Tue May 31, 5:49PM CDT
OTC Markets Group Inc. (OTCQX: OTCM), operator of financial markets for 10,000 U.S. and global securities, today announced the lineup of OTCQX® Best and OTCQB® Venture Market companies presenting at the Marcum MicroCap Conference, taking place June 1-2nd at the Grand Hyatt New York. The Marcum MicroCap Conference, is dedicated to providing a forum where publicly traded companies with less than $500 million in market capitalization can network with the investment community. The Conference will feature presentations by CEOs and CFOs from various industry sectors, expert panels, and the opportunity to meet with management of presenting companies on a one-on-one basis.
LTEA: 4.39 (+0.18)
Relmada Therapeutics to Present at the 5th Annual Marcum MicroCap Conference
PR Newswire - Thu May 26, 7:30AM CDT
Relmada Therapeutics, Inc. (OTCQB: RLMD), a clinical-stage company developing novel therapies for the treatment of chronic pain, announced today that it will present at the 5th Annual Marcum MicroCap Conference on Thursday, June 2, 2016 in New York City at the Grand Hyatt Hotel.
Relmada Therapeutics Announces Promotion of Michael D. Becker to Chief Financial Officer
PR Newswire - Mon May 16, 7:30AM CDT
Relmada Therapeutics, Inc. (OTCQB: RLMD), a clinical-stage company developing novel therapies for the treatment of chronic pain, today announced the promotion of Michael D. Becker to chief financial officer, effective as of May 11, 2016.
Relmada Therapeutics Announces Results of In Vivo Study Showing d-Methadone has Antidepressant-like Effects
PR Newswire - Wed May 04, 7:30AM CDT
Relmada Therapeutics, Inc. (OTCQB: RLMD), a clinical-stage company developing novel therapies for the treatment of chronic pain, today announced the results of an in vivo study showing that administration of d-Methadone (REL-1017), a N-methyl-d-aspartate (NMDA) receptor antagonist, results in antidepressant-like effects. Results are shown to be comparable to those achieved in similar treatment models using ketamine.
Relmada Therapeutics to Present at the Joseph Gunnar "Pioneers 2016" Conference
PR Newswire - Thu Apr 28, 7:30AM CDT
Relmada Therapeutics, Inc. (OTCQB: RLMD), a clinical-stage company developing novel therapies for the treatment of chronic pain, today announced that it will present at the Joseph Gunnar "Pioneers 2016" Conference on May 5, 2016 at the New York Palace Hotel in New York City.
Relmada Therapeutics Provides Additional Details Regarding Upcoming R&D Day
PR Newswire - Tue Apr 26, 7:30AM CDT
Relmada Therapeutics, Inc. (OTCQB: RLMD), a clinical-stage company developing novel therapies for the treatment of chronic pain, today announced that it will hold its first R&D Day on May 4, 2016, from 10:00 a.m. to 12:00 p.m.
Relmada Therapeutics' Michael Becker Interviewed by The Life Sciences Report
Marketwired - Thu Apr 21, 8:02AM CDT
To treat chronic pain without risk of addiction is to straddle a knife's edge. But Relmada Therapeutics Inc. (OTCQB: RLMD) has a small fleet of compounds in development that address both sides of an issue that has become a newsmaker, given the recent upsurge in heroin addiction and the ever-present conundrum of alleviating severe pain in chronic disease and after surgery. In this interview with The Life Sciences Report, Relmada's Michael Becker describes the company's programs, which are advancing steadily toward the marketplace.
Relmada Therapeutics, Inc. Provides Update on Nasdaq Up-Listing Process
PR Newswire - Thu Apr 14, 7:30AM CDT
Relmada Therapeutics, Inc. (OTCQB: RLMD) a clinical-stage company developing novel therapies for the treatment of chronic pain, today provided investors with an update regarding the Company's qualification for up-listing to The Nasdaq Capital Market ("Nasdaq"
. As previously disclosed, the Company submitted an initial listing application with Nasdaq in the second half of 2015. The Company now believes that it satisfies each of the exchange's applicable listing requirements, with the exception of the $4.00 bid price requirement. In accordance with the Nasdaq Listing Rules, the Company's stock price must close at or above $4.00 per share for 30 of the most recent 60 trading days in order for the Company to be eligible to list. UPDATE -- OTCQX and OTCQB Companies to Present at 2016 Roth Conference
PR Newswire - Mon Mar 14, 6:00AM CDT
OTC Markets Group Inc. (OTCQX: OTCM), operator of financial markets for 10,000 U.S. and global securities, today announced the lineup of OTCQX® Best and OTCQB® Venture Market companies presenting at the 28th Annual ROTH Conference, taking place March 13-16 at the Ritz-Carlton in Dana Point, CA. The ROTH Conference, hosted by ROTH Capital Partners, LLC, is one of the largest small-cap investment conferences in the U.S., featuring presentations by senior executives from hundreds of public and private companies in a wide variety of sectors.
VRAY: 3.37 (+0.13), DMPI: 6.80 (-0.03), CDXC: 4.00 (-0.39), EKSO: 3.85 (-0.10)
OTCQX And OTCQB Companies To Present At 2016 ROTH Conference
PR Newswire - Thu Mar 10, 6:00AM CST
OTC Markets Group Inc. (OTCQX: OTCM), operator of financial markets for 10,000 U.S. and global securities, today announced the lineup of OTCQX® Best and OTCQB® Venture Market companies presenting at the 28th Annual ROTH Conference, taking place March 13-16 at the Ritz-Carlton in Dana Point, CA. The ROTH Conference, hosted by ROTH Capital Partners, LLC, is one of the largest small-cap investment conferences in the U.S., featuring presentations by senior executives from hundreds of public and private companies in a wide variety of sectors.
VRAY: 3.37 (+0.13), DMPI: 6.80 (-0.03), CDXC: 4.00 (-0.39), EKSO: 3.85 (-0.10)
Relmada Therapeutics to Present at the 18th Annual BIO CEO & Investor Conference
PR Newswire - Tue Feb 02, 7:00AM CST
Relmada Therapeutics, Inc. (OTCQB: RLMD) a clinical-stage company developing novel therapies for the treatment of chronic pain, announced today that the Company will present at the 18th Annual BIO CEO & Investor Conference on Monday, February 8th at 3:30 p.m. Eastern Time. The conference will take place at the Waldorf Astoria Hotel in New York City.
Relmada Therapeutics Files Amended Complaint Against Laidlaw and Its Principals, Matthew Eitner and James Ahern
PR Newswire - Tue Jan 26, 6:00AM CST
Relmada Therapeutics, Inc. (OTCQB: RLMD) ("Relmada" or the "Company"
, a clinical-stage company developing novel therapies for the treatment of chronic pain, today announced that it has filed a motion to amend its complaint against Laidlaw & Company (UK) Ltd. ("Laidlaw" in the U.S. District Court for the District of Nevada. The motion to file an amended complaint is part of the lawsuit that the Company had previously filed in the Nevada District Court. The amended complaint includes an additional legal claim based on Laidlaw's breach of the fiduciary duty that it owed to Relmada when Laidlaw disclosed confidential information that it acquired in its capacity as the Company's investment banker. Relmada is also seeking monetary damages arising from fees and costs that it incurred responding to Laidlaw's false and misleading proxy materials in December 2015. Relmada Therapeutics Selected to Present at 2016 Biotech Showcase(TM) in San Francisco
PR Newswire - Mon Jan 11, 7:00AM CST
Relmada Therapeutics, Inc. (OTCQB: RLMD) a clinical-stage company developing novel therapies for the treatment of chronic pain, announced today that the company has been selected to present at the 8th Annual Biotech Showcase(TM) Conference at 2:00 PM Pacific Time (5:00 PM Eastern Time) on Wednesday, January 13, 2016. The presentation will take place in Track C - Mission II at the Parc 55 Hotel in San Francisco.
Relmada Therapeutics Successfully Completes Multiple Ascending Dose Study of d-Methadone for Neuropathic Pain
PR Newswire - Mon Jan 04, 7:00AM CST
Relmada Therapeutics, Inc. (OTCQB: RLMD) ("Relmada" or the "Company), a clinical-stage company developing novel therapies for the treatment of chronic pain, announced today that it completed its multiple ascending dose ("MAD"
study with d-Methadone (dextromethadone, REL-1017), its novel, N-methyl-D-aspartate ("NMDA" receptor antagonist being developed for the treatment of neuropathic pain. Relmada previously completed a single ascending dose ("SAD" study in March 2015. The design of the Company's Phase II proof-of-concept study in neuropathic pain, anticipated to start in the first half of 2016, will be based on this study's findings. Relmada Therapeutics Announces Results of Annual Meeting of Stockholders
PR Newswire - Wed Dec 30, 10:55AM CST
Relmada Therapeutics, Inc. (OTCQB: RLMD) ("Relmada" or "the Company"
, a clinical-stage company developing novel therapies for the treatment of chronic pain, today announced that, at the Company's 2015 Annual Meeting of Stockholders, Relmada stockholders voted to elect all of Relmada's director nominees: Shreeram Agharkar, PhD, and Maged Shenouda, R. Ph., MBDA. The final tabulation indicates that more than 94% of votes cast at the Annual Meeting were in support of Messrs. Agharkar and Shenouda. Relmada Therapeutics Recommends Stockholders Vote "FOR" Relmada's Director Nominees on the WHITE Proxy Card Today
PR Newswire - Mon Dec 28, 7:30AM CST
Relmada Therapeutics, Inc. (OTCQB: RLMD) ("Relmada" or the "Company"
, a clinical-stage company developing novel therapies for the treatment of chronic pain, today reiterated its Board's unanimous recommendation that stockholders vote "FOR" the Company's highly qualified, independent director nominees - Shreeram Agharkar, PhD, and Maged Shenouda R. Ph., MBA - on the WHITE proxy card today. U.S. Federal Court Grants Preliminary Injunction Against Laidlaw & Company and its Principals Matthew Eitner and James Ahern
PR Newswire - Wed Dec 23, 7:30AM CST
Relmada Therapeutics, Inc. (OTCQB: RLMD) ("Relmada" or the "Company"
, a clinical-stage company developing novel therapies for the treatment of chronic pain, announced that following a hearing, the U.S. District Court for the District of Nevada granted Relmada's request and granted a Preliminary Injunction against Laidlaw & Company (UK) Ltd. and its principals, Matthew Eitner and James Ahern. The Court Order enjoins Laidlaw and Messrs. Eitner and Ahern from "continuing to disseminate false and misleading proxy materials." Corrected Press Release--Shareholder Value Creation Committee Will Continue To Fight For Shareholder Rights
PR Newswire - Mon Dec 21, 2:10PM CST
The Committee of Relmada Shareholders for Value Creation, (the Shareholder Value Creation Committee) issued its press release on December 11, 2015, which press release omitted a sentence regarding the retraction of certain previously issued open letters to shareholders and characterized the temporary restraining order as preventing the solicitation of proxies, the characterization of which is being corrected herein. The corrected press release is as follows:
